Lisata Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Basking Ridge, NJ
LSTA chart
What traders are saying about $LSTA
Latest postsLisata Therapeutics, Inc. news
- Lisata Therapeutics stockholders approve equity plans and reverse stock split By Investing.com
Investing.com South Africa ·
- Lisata Therapeutics Stockholders Approve Equity Plans, Defer Conversion Vote
TipRanks ·
- Form 8K Lisata Therapeutics Inc For: 9 November By Investing.com
Investing.com Canada ·
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
Yahoo Finance ·
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics,
GlobeNewswire ·
- In people with very high blood fats, an experimental drug lowered levels by up to 72.2%. Blood sugar control did not worsen.
Stock Titan ·
- Lisata Therapeutics, Inc. (LSTA) Seasonal returns chart
Yahoo Finance UK ·
- Lisata Therapeutics, Inc. (0HS8.L) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
Yahoo Finance ·
- Marea will join three November conferences; two talks will stream live online.
Stock Titan ·
- Lisata Therapeutics subsidiary Marea Therapeutics to participate in three investor conferences in November
Proactive financial news ·
- Lisata adds biopharma finance veteran Jeffrey Farrow to board
proactiveinvestors.com ·
Lisata Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 |
| Net income | -$17.0M | -$20.0M | -$21.0M | -$54.2M |
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 |
| Total assets (year end) | $17.7M | $35.0M | $54.7M | $73.0M |
| Cash and equivalents (year end) | $16.0M | $16.2M | $22.6M | $32.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Lisata Therapeutics, Inc.
- Ticker
- LSTA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Basking Ridge, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., NeoStem, Inc.
Frequently asked questions
What exchange is Lisata Therapeutics, Inc. listed on?
Lisata Therapeutics, Inc. trades on the Nasdaq under the ticker symbol LSTA.
What industry is Lisata Therapeutics, Inc. in?
Lisata Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Lisata Therapeutics, Inc. headquartered?
Lisata Therapeutics, Inc.'s business address on file with the SEC is in Basking Ridge, NJ.
When does Lisata Therapeutics, Inc.'s fiscal year end?
Lisata Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Lisata Therapeutics, Inc. report?
Lisata Therapeutics, Inc. reported $170,000 in revenue for calendar year 2025, according to its SEC filings.